Large Israeli study shows Pfizer's vaccine cuts symptomatic COVID-19 by 94 percent


Israel has now fully vaccinated 28 percent of its population against COVID-19 and administered the first dose to 42 percent of its nine million inhabitants, and its data is very promising. Clalit, the largest of Israel's four health-care providers, reported Sunday that the Pfizer-BioNTech vaccine has resulted in a 94 percent drop in symptomatic COVID-19 infections among those who have gotten both doses and a 92 percent decline in severe illness.
Clalit compared 600,000 Israelis who have been fully vaccinated against an equal number who have not, pairing vaccinated people and non-vaccinated people with a similar age and health profile. The majority of people studied were age 16 to 59, but 170,000 of the 600,000 Israelis were 60 or older. "It is now unequivocal that Pfizer's vaccine against the coronavirus is incredibly effective in real life one week after the second dose, just as was found in the clinical study," Ran Balicer, Clalit's chief innovation officer and one of the study's authors, said in a statement Sunday. He said the vaccine is even more effective two weeks after the second shot.
Israel plans to inoculate most of its population by March, and in return for its early access to the Pfizer vaccine, the country agreed to share its data on vaccine safety, effectiveness, and side effects, The Wall Street Journal reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Overall, COVID-19 cases have dropped by 41 percent in Israel while hospitalizations have dropped by a third, public health experts Ezekiel Emanuel, Céline Gounder, Michael Osterholm, Luciana Borio, Atul Gawande, and Rick Bright write in a USA Today op-ed. "All seven COVID-19 vaccines that have completed large efficacy trials" appear "to be 100 percent effective for serious complications" and death, they added, so "our advice is simple: Take whatever vaccine is offered to you. Right now, all of the vaccines are the 'best.'"
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
-
Crypto firm Coinbase hacked, faces SEC scrutiny
Speed Read The Securities and Exchange Commission has also been investigating whether Coinbase misstated its user numbers in past disclosures
-
Starbucks baristas strike over dress code
speed read The new uniform 'puts the burden on baristas' to buy new clothes, said a Starbucks Workers United union delegate
-
Warren Buffet announces surprise retirement
speed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement
-
Trump calls Amazon's Bezos over tariff display
Speed Read The president was not happy with reports that Amazon would list the added cost from tariffs alongside product prices
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores